Neoantigen peptides carry the tumor-specific mutations that make personalized cancer vaccines possible, but their variable length, charge, and hydrophobicity make reliable synthesis difficult. This article examines GenScript's research-grade to GMP neoantigen peptide services, including the NeoPre…
Researchers building personalized cancer vaccines need neoantigen peptides that are sequence-correct, pure enough for the intended application, and available at the required scale, from milligram-level screening panels to GMP-grade material for injection. GenScript runs a neoantigen peptide service that covers that range: a sequence-based difficulty predictor called NeoPre, microwave, liquid-phase, and solid-phase synthesis platforms, research-grade and GMP production lines, and a Grade A isolator for sterile filling. The capability list is specific, but nearly every figure attached to it is vendor-reported and independently unverified. This article presents the claims as claims, then sets them against the published evidence.
Neoantigens are peptides derived from tumor-specific mutations. A mutation alters a protein sequence, the altered protein is degraded, and the resulting novel peptides can be presented on MHC molecules where T cells sample them. Because these peptides are absent from healthy tissue and are not recognized as self-antigens, T cells can respond to them strongly. That is the rationale stated in GenScript's materials, and it matches what the literature shows: neoantigen-specific T-cell receptors have been characterized at atomic resolution PMID 39576860 , and neoantigen epitopes have been identified in tumor types including cervical cancer PMID 40826144 .
Two properties shape vaccine design. First, because neoantigens are expressed only in tumor tissue, targeting them avoids the on-target, off-tumor toxicity that limits many shared tumor antigens. Second, a neoantigen that has already formed is unlikely to mutate again, so the tumor faces a higher barrier to escaping a response directed at it. No single epitope is guaranteed to persist, however, which is why personalized vaccines typically target several neoantigens at once; simultaneous targeting reduces the chance that a tumor escapes by losing one antigen. Each neoantigen can also be matched to specific T cell receptors, allowing the immune response to be tested in vitro before the peptide is used therapeutically.
Ordering peptides for this work means confronting a wide length range. Some neoantigen peptides fall in the 9 to 11 amino acid range typical of MHC class I epitopes, while others exceed 25 amino acids, the long-peptide format used to recruit both CD4+ and CD8+ T cells. The range matters because synthesis difficulty rises with length and sequence composition.
The difficulties are chemical. Solid-phase synthesis builds a peptide chain one residue at a time, and each coupling step risks incompleteness and side reactions. Neoantigen sequences are awkward because the mutations that create them also change their chemistry. GenScript identifies three recurring problems: length, charge-modifying amino acids, and hydrophobic side chains. Peptides over 20 amino acids are particularly challenging because coupling yields fall and the accumulation of truncated by-products rises. Hydrophobic side chains introduced by a mutation can cause the growing chain to aggregate and can leave the final product poorly soluble in water, both of which complicate purification. The same hydrophobicity can interfere with characterization, since aggregation distorts high-performance liquid chromatography and mass spectrometry readouts.
Applications add a second layer of difficulty because they demand different specifications. A high-throughput screening panel may tolerate a lower percentage of target peptide, while a clinical batch must meet defined purity, mass, yield, and target-peptide content. GenScript's materials argue that this variety is exactly why it is hard to find a reliable provider, a fair point that cuts both ways: buyers need to specify the application up front, and vendors need to be explicit about what their release tests measure.
GenScript's answer to sequence-dependent difficulty is NeoPre, a predictive algorithm that scores synthesis difficulty from the peptide sequence alone and recommends a synthesis strategy before the first coupling. The company reports a synthesis success rate above 98% for projects planned with NeoPre and a 99% success rate across customer projects overall. Both figures are vendor-reported and not independently verified.
The platform is then selected from three technologies according to difficulty: microwave-assisted synthesis, which shortens coupling cycles; liquid-phase synthesis, which suits longer or more hydrophobic sequences where solid-phase impurity accumulation becomes limiting; and solid-phase synthesis, the standard approach for most peptides. GenScript quotes an overall turnaround of about 10 days for peptide synthesis and a fastest delivery time of 4 weeks for neoantigen peptides. The vendor does not specify which scope each number covers.
Product specifications, also as reported: neoantigen peptides up to 35 amino acids in length with purity above 95% under GMP-compliant conditions, and all peptides released through AccuPep, the company's quality-control program, which applies more than 14 types of tests. For sequence optimization, GenScript offers library design tools including alanine scanning to identify residues critical for binding, overlapping peptides to map T-cell epitopes across a region, and T-cell truncation to define the minimal epitope recognized by a given receptor. The full set of claimed figures appears below.
A success rate figure is only as meaningful as its definition. A 98% synthesis success claim could mean the share of sequences that reached the requested purity and quantity on the first attempt, or something looser, such as the share of projects that eventually delivered material. Buyers should ask any provider to define success before comparing rates.
Vendor-reported figures for GenScript's neoantigen peptide service. None are independently verified.
| Metric | Reported value | What it measures |
|---|---|---|
| NeoPre-assisted synthesis success | 98% | Share of projects planned with NeoPre that succeeded |
| Customer project success rate | 99% | Claimed success across customer projects |
| Customers served | 300+ | Academic and industrial customers |
| GMP batches delivered | 90+ | Batches from the GMP line |
| GMP projects supported | 20+ | Projects using the GMP line |
| Overall synthesis turnaround | ~10 days | Quoted turnaround for peptide synthesis |
| Fastest neoantigen delivery | 4 weeks | Quoted fastest delivery |
| Maximum peptide length | 35 amino acids | Length limit |
| Purity | 95% | Purity of provided peptides |
| QC test types | 14 | Tests in the AccuPep suite |
GenScript offers three product lines that differ by sterility and intended use. Non-sterile neoantigen peptides come from both the research-use-only line and the GMP facility. Sterile peptides come only from the GMP facility, where a Grade A isolator is used for sterile filtration and aseptic filling, the operations that make material suitable for human injection. The line you choose should follow the application: screening does not require GMP material, while clinical use requires the sterile GMP route.
| Product line | Sterility | Facility | Typical use |
|---|---|---|---|
| RUO non-sterile | Non-sterile | RUO line | Screening, assay development |
| GMP non-sterile | Non-sterile | GMP facility | Preclinical and analytical work |
| GMP sterile | Sterile Grade A isolator | GMP facility | Human injection |
In manufacturing terms, GenScript reports delivery of more than 90 GMP batches and support for more than 20 GMP projects. There is no public record to check those counts against.
GMP manufacturing for peptides extends beyond filling. Synthesis, purification, and release testing all operate under documented quality systems, and the final certificate of analysis should evidence identity, purity, and, for sterile products, sterility. GenScript's description emphasizes the Grade A isolator, the last step in the chain, but the release certificate is what a buyer's quality team will actually scrutinize. Request one with every batch.
Compliance is handled unusually. The Rx-360 Joint Audit Program, a pharmaceutical supply-chain auditing initiative launched in 2013, audited GenScript's Zhenjiang site under audit identifier JA-3136 on 25 to 28 March 2025, and the audit report is available for licensing. A buyer that licenses the report can assess supplier compliance without arranging an on-site audit, which shortens the qualification timeline. The vendor does not disclose what the audit found, so the report, not the announcement, is what a quality team should review.
None of the preceding claims comes from a peer-reviewed study of GenScript's service. The literature does establish that neoantigen peptide vaccination, the approach the service supplies, is biologically active and is already being tested in people. The vendor figures should be read in that light.
In preclinical models the results are strong. A personalized neoantigen peptide vaccine combined with PD-1 blockade produced 80% durable tumor regression in orthotopic mouse models of hepatocellular carcinoma, with long-term immune memory traced to increased infiltration of CD8+ tissue-resident memory T cells PMID 36113894 . A neoantigen hydrogel vaccine combined with PD-1 and CTLA-4 blockade increased intratumoral neoantigen-specific CD8+CD69+ T cells in liver metastasis models and induced durable antitumor immunity with no obvious toxicity PMID 39694701 . In mouse colorectal tumors, PD-L1 deletion unmasked three immunogenic neoantigens and their cognate TCRs, and neoantigen-pulsed dendritic cell therapy reversed tumor tolerance PMID 32629606 .
A 2025 review of neoantigen-based cancer vaccines reports that peptide, mRNA, and DNA platforms have all shown feasibility, safety, and immunogenicity across solid tumors. It also reports that peptide-pulsed dendritic cell vaccines elicited higher per-epitope CD8+ T-cell responses than mRNA vaccines, and that adjuvant-setting trials in melanoma, glioblastoma, and pancreatic cancer have shown encouraging relapse-free outcomes PMID 41514653 . These are the clinical contexts in which GMP-grade neoantigen peptides will be used.
Structural and translational studies fill in the mechanism. A human TCR bound to NRAS Q61K and Q61R neoantigens presented on HLA-A1 was resolved by crystallography, showing how the TCR achieves specificity for the mutant peptides over wild-type NRAS PMID 39576860 . In cervical cancer, multi-omics analysis of TCGA data identified the highly mutated gene PCLO and validated two neoantigen peptides, SISRFTLEK and LSEAGHFFY, with strong predicted binding and in vivo immunogenicity PMID 40826144 .
Registered studies use several delivery formats, from autologous dendritic cells pulsed with neoantigen peptides to synthetic long peptides injected directly as a vaccine:
| Trial ID | Phase | Disease | Status | Enrolment |
|---|---|---|---|---|
| NCT05741242 | 1b/2 | Local or metastatic solid tumors | Enrolling by invitation | 136 |
| NCT06342908 | 1 | H3 G34-mutant diffuse hemispheric glioma | Active, not recruiting | 6 |
| NCT04105582 | 1 | Triple negative breast cancer | Completed | 5 |
| NCT04364230 | 1/2 | Melanoma, ocular melanoma | Completed | 22 |
| NCT05641545 | 1 | Advanced renal cell carcinoma | Terminated | 1 |
NCT05741242 is a Phase 1b/2 study of neoantigen synthetic long peptide vaccines in 136 patients with local or metastatic solid tumors, the format most directly relevant to peptide synthesis at scale. The terminated single-patient renal cell carcinoma trial, NCT05641545, is a reminder that individual programs fail as well as succeed.
None of these studies is linked to GenScript's service. The only customer application described in the vendor's materials comes from 3T Biosciences, which reports using GenScript since 2017 to generate thousands of peptides for T-cell receptor research and credits GenScript's peptide chemists with enabling the screening of hundreds of neoantigens in mice to test the generalizability of its SNP-7/8a technology. That is a customer testimonial relayed by the vendor, not independent evidence of output quality.
Practical points for a researcher or buyer:
Open questions the vendor does not answer: how NeoPre scores difficulty internally, which specific tests the AccuPep suite contains, pricing and minimum order quantities for research-grade versus GMP peptides, maximum GMP production capacity, and how this service compares with alternatives on cost, speed, and quality. No clinical outcomes for peptides produced by this service have been published. Until independent data appear, the reported figures should be treated as targets to verify with your own analytical testing and qualification runs.
Vendors referenced: Genscript.
Related reading: How Chameleon Cyclic Peptides Cross Membranes for Oral Drugs, Five Enzymatic Routes to Oligopeptides and Short Peptide Synthesis, How Cyclic Peptides Cross Membranes: Mechanisms and Design Rules, Enzymatic Routes to Short Peptides: Mechanisms, Uses, Limits.